Share Email Print

Proceedings Paper

Nanophotonic ensembles for targeted multi-photon photodynamic therapy
Author(s): Charles W. Spangler; Fanqing Meng; Aijun Gong; Mikhail A. Drobizhev; Aliaksandr Karotki; Aleksander Rebane II
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

There has been a dramatic increase in the application of new technologies for the treatment of cancerous tumors over the past decade, but for the most part, the treatment of most tumors still involves some combination of invasive surgery, chemotherapy and radiation treatments. Photodynamic therapy (PDT), which involves the activation of an administered compound with laser light followed by a series of events leading to programmed cell death of the tumor, has been proposed as a noninvasive alternative treatment to replace the standard surgery/chemotherapy/radiation protocol. However, currently approved PDT agents operate in the Visible portion of the spectrum, and laser light in this region cannot penetrate the skin more than a few millimeters. Two-photon irradiation using more highly penetrating Near-infrared (NIR) light in the tissue transparency window (700-1000 nm) has been proposed for the treatment of subcutaneous tumors, but most porphyrins exhibit extremely small two-photon cross-sections. Classical PDT also suffers from the lengthy time necessary for accumulation at the tumor site, a relative lack of discrimination between healthy and diseased tissue, particularly at the tumor margins, and difficulty in clearing from the system in a reasonable amount of time. We have recently discovered a new design paradigm for porphyrins with greatly enhanced two-photon cross-sections, and are now proposing a nano-ensemble that would also incorporate small molecule targeting agents, and possibly one-photon NIR imaging agents along with these porphyrins in one therapeutic agent. Thus these ensembles would incorporate targeting/imaging/PDT functions in one therapeutic agent, and hold the promise of single-session outpatient treatment of a large variety of subcutaneous tumors.

Paper Details

Date Published: 1 June 2004
PDF: 8 pages
Proc. SPIE 5331, Nanobiophotonics and Biomedical Applications, (1 June 2004); doi: 10.1117/12.532510
Show Author Affiliations
Charles W. Spangler, MPA Technologies, Inc. (United States)
Fanqing Meng, MPA Technologies, Inc. (United States)
Aijun Gong, MPA Technologies, Inc. (United States)
Mikhail A. Drobizhev, Montana State Univ. (United States)
Aliaksandr Karotki, Montana State Univ. (United States)
Aleksander Rebane II, Montana State Univ. (United States)

Published in SPIE Proceedings Vol. 5331:
Nanobiophotonics and Biomedical Applications
Alexander N. Cartwright, Editor(s)

© SPIE. Terms of Use
Back to Top